Member Info for BoNidel

Finally some news! I think it’s a good omen when I post.

I’ll be VERY interested to see how it’s priced with regards to the offering!

It would be a blessing to get some dough back to get my head near water with TILS and also be able to hold a fair whack of these through to commercialisation.

And just as I post we get an update.

Maybe I ought to post more!..

Are we going to get a press release any time soon about updates?

Pathetic! Either nothing is happening or something is happening and the market isn’t being made aware. Either outcome is equally poor as usual

Still waiting for An update on this.

Reading about the rise in VRFB’s, maybe there is more than meets the eye here.

There is also cellcubes new home power system (or so it seems)

Maybe something fairly decent is coming here in terms of tech.

Reverse it all into must, then you’ve got a full chain of mining/ resources into production of VRFBS under one roof.

If successful it certainly would be an interesting proposal and potentially a solid situation to raise against to fund big growth/expansion plans.

what GC say about accustem being used for different purposes?

When are we going to get an accustem update ffs!!

Looking forward to it.

I bet it starts - “foralumab is the only fully human anti cd3 blah blah”. Always what it can do, not what they’re going to do with it.

Is this an accustem call as well? Some people have insinuated accustem will be involved as well? Do we get to meet Wendy blosser tomorrow and see what accustem is doing?

“ Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012.”

Please can you publish a link to GC being involved with exact sciences or genomic health? I think you’ve dropped a clanger here. Not that it matters as the principle of what you are saying is similar.

It was a typo,

He sold "Inhibitex" as far as I'm aware.

as for deramping, i have blown hot and cold on this for the last year or since the TILS SP collapse.

im underwater on tils and accustem so i dont really think its in my favour to deramp..

I am seriously peeved with the managements handling of the corporate actions and the lack of Comms.

I have made it clear on numerous times that accustem could be a bargain at these prices hence buying but have said it’s blind gambling really as nothing has happened for years.

I want accustem to fly so I can get out of jail on TILS somewhat. I would like to hold a lesser number of shares for Tiziana long term as I can see the potential but after the last 2-3 years I’m severely disheartened and wouldn’t want to have as much exposure.

Granted, as said before, all biotech sector is down.

I’m not deramping to short or to buy, quite the contrary I would like to raise awareness so ACUT gets some volume and can maybe uplist to NASDAQ!

I even told here of the price of my recent purchases.

Sorry chap I think you’re getting your wires crossed.

He sold inhibited to BMS.

Stemprinter was shown as 40% better than the current market leader - OncotypeDX.

Oncotype DX is owned by Exact sciences.

Exact sciences bought out genomic health and acquired oncotype DX as part of a $2.8BN deal.

Some analysts put the value of accustem at 10% if the value of this deal so $280m MCAP which exceeded tils valuation at the time of the report (IIRC).

Current MCAP of Accustem is around $7m dollars so around 1/40th of what was previously touted…

In “old” accustem shares (from the tils Uk entitlements) that makes the equivalent of each accustem share around 2.6p if I’m right! Certainly a lot less than having to hold tils shares @180p to get the same!

1000 accustem shares now roughly costs £500 odd quid give or take a few hundred.

Previously to get 1000 shares today you’d have needed 20,000 tils shares at a cost of around £36k at ex date

I believe the last few purchase have been around 0.52-0.57cents (45-48p) sterling at the time.

Obviously you have higher dealing charges with HL on these (if that’s who you use).

On the plus side the old accustem entitlements and new shares all seem to be the same now so something must have reconciled back end.

MCAP between 5-10m for this is a lot less than the estimated $280m!!!

To be honest, it may well work in my favour but it sure does stink.

I bought another 2000 accustem shares recently. I would have had to have held around £72k of tils shares to get that entitlement. Why bother being a long term holder ? You just get shafted by the BOD in my opinion. I’m in here as I can’t get out. Accustem may pay dividends but I’m blind gambling currently. The number of accustem shares I now have (as I’ve kept buying) would have required me to have a huge wedge of cash in tils. What is going on. Why haven’t new management done an interview or anything to encourage liquidity and shareholders ?

Great news but to be honest, at this point, they could enrol rumpelstiltskin and the markets still wouldn’t care.

Biotech is suffering still but the damage done here is still massive.

Ridiculous issues with the Nasdaq single listing/LSE delisting with NO explanation.

Accustem 2 years with little results and ridiculously low MCAP with NO explanation.

It goes on and on.

Since the Ex date soon. Indefensible.

2 years and practically nothing? 20 for 1 consolidation in the UK which could be 15 for 1 again shortly so 300 - 1 consolidation equivalent soon with an MCAP of $5m when Tiziana advertised zacks or HC Wainwrights broker forecast valuation of $280m (10% of the genomic health take over by exact sciences - $2.8bn)

At what point do we admit we’ve been diddled?

Honestly, can any of the usuals here give us a glimmer of hope? Defend this somehow?

Please feed me something to defend this.

Yes it is a hard one. I think some holders like us are up to their b*lls though so have no choice but to hold.

They still have a pile of cash for a buyback if needs be or does it end up on the OTC as they need the cash for the trials!

Alzheimer’s trial probably maybe sometime next year (although probably not if the previous sh*t) management is anything to go by.

If the MS trials continue as super successful and go in to a full trial then I can see there being interest. Hopefully there’s enough cash to fund operations for next year or two and also for the buybacks should they be needed.

GC is no mug but shareholders have been shafted here, I stand by that.

I have bought some more TLSA and Accustem through in the hope they come back. Accustem is surely a bargain if it does come to fruition or biotech comes back to any degree?

To be fair, why bother even voting for something that probably doesn’t even exist anyway.

No interviews yet from the newly appointed top brass, no fund raise, no Nasdaq uplisting (granted they have said in the soliciting materials they need another reverse split to meet the price requirements).

2 years now and accustem hasn’t delivered anything, any some holders apparently still haven’t received their shares.

Absolutely criminal and totally opaque.

Is set for today and started 40 minutes ago (correct me if I’m wrong).

I wonder if there is a placing/fund raise earmarked for when/if the reverse split is approved?

Shame there’s no live stream for the AGM.

Are you telling me you still aren’t able to trade your Tiziana share since the Nasdaq switch?

You can imagine the conversation now.

Salary is xxxx
Share options are xxxx

But XXXX additional salary I would expect you to spend on shares/director buys.

Realistically, an insider buy such as this from a new starter could just be treated as being given free shares. Not that I’m suggesting foul play, but come on.

TILS is still on its arse after a successful suckering for shareholders that got involved with the covid hype.

Always nice to see GC buying but I really don’t know where the SP is heading. The covid volatility certainly seems to be long gone